Notes in 01. Abbreviation and 02. Groupings

To Subscribe, use this Key

Status	Last Update	Fields
Published	10/21/2024	Second-line Drugs are given to {{c1::MDR-TB}}
Published	10/21/2024	{{c1::Multiple Drug Resistant Tuberculosis (MDR-TB)}}Resistance to both {{c1::Isoniazid}} AND {{c1::Rifampicin}} (not OR), presence of resistance to b…
Published	10/21/2024	{{c1::Mono-resistance}} refers to the resistance to {{c1::one first-line}} anti-TB drug only
Published	10/21/2024	{{c1::Poly-resistance}} refers to the resistance to {{c1::more than one first-line}} anti-TB drug, other than both isoniazid and rifampicin
Published	10/21/2024	{{c1::Extensive Drug Resistance (XDR)}} is a combination of {{c1::MDR + 2nd line drugs}}
Published	10/21/2024	GIve the Medicine and its Abbreviation{{c1::Levofloxacin}} - {{c1::Lfx}}{{c1::Moxifloxacin}} - {{c1::Mfx}}{{c1::Bedaquiline}} - {{c1::Bdq}}{{c1::Linez…
Published	10/21/2024	If BPaLM is not applicable to patient (depending on the criteria) then use {{c1::Individualized treatment regimen (ITR)}}
Published	10/21/2024	Group A based on the ITR is considered:▪ {{c1::Highly bactericidal, most effective}}▪ {{c1::High sterilizing activity}}▪ {{c1::High resistance prevent…
Published	10/21/2024	Group B based on the ITR is considered:▪ {{c1::Moderate to high bactericidal activity}}▪ {{c1::Low sterilizing activity}}
Published	10/21/2024	Bedaquiline→ Cannot be given to {{c1::children}}→ Effectivity is only {{c1::6 months}} lang→ {{c1::‘off-label use’}} if more than 6 months
Published	10/21/2024	{{c1::Levofloxacin}} and {{c1::Moxifloxacin}} are both {{c1::fluoroquinolones*}} cannot be given simultaneously, only choose one.
Published	10/21/2024	● Latent TB → {{c1::Rifapentine}}● Active TB → {{c1::Rifampicin}}
Status	Last Update	Fields